Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease
S Gaillard, S Dupuis-Girod, F Boutitie, S Rivière, S Morinière, P-Y Hatron, G Manfredi, P Kaminsky, A-L Capitaine, P Roy, F Gueyffier, H Plauchu, ATERO Study Group, Frederic Faure, Olivier Merrot, Pascal Magro, Odile Boute, Elisabetta Buscarini, Roger Jankowski, Lelia Pruna, Brigitte Gilbert-Dussardier, Jean-Michel Klossek, Romain Corre, Philippe Delaval, Emmanuel Babin, Jacques Perret, Marie-France Carette, Valerie Franco-Vidal, Pierre Duffau, Jean-Robert Harle, S Gaillard, S Dupuis-Girod, F Boutitie, S Rivière, S Morinière, P-Y Hatron, G Manfredi, P Kaminsky, A-L Capitaine, P Roy, F Gueyffier, H Plauchu, ATERO Study Group, Frederic Faure, Olivier Merrot, Pascal Magro, Odile Boute, Elisabetta Buscarini, Roger Jankowski, Lelia Pruna, Brigitte Gilbert-Dussardier, Jean-Michel Klossek, Romain Corre, Philippe Delaval, Emmanuel Babin, Jacques Perret, Marie-France Carette, Valerie Franco-Vidal, Pierre Duffau, Jean-Robert Harle
Abstract
Background: Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder associated with abnormal angiogenesis and disabling epistaxis. Tranexamic acid (TA) has been widely used in the treatment of these severe bleeds but with no properly designed trial.
Objectives: To demonstrate the efficacy of TA in epistaxis in HHT patients and to explore its safety of use.
Patients/methods: A randomized, placebo-controlled, double-blind, cross-over trial was conducted. Participants were randomized to receive TA (3 g a day) then placebo or the opposite sequence. The main analysis compared intra-individual mean duration of epistaxis under TA vs. placebo on a log scale. The primary outcome was the mean duration of epistaxis per month, assessed with specific grids to be completed by participants. The number of epistaxis episodes was recorded as a secondary outcome.
Results: A total of 118 randomized patients contributed to the statistical analysis. The mean duration of epistaxis per month was significantly shorter with TA than placebo (0.19 on the log scale; SD = 0.07; P = 0.005), corresponding to a decrease of 17.3% (15.7 min) in the duration of epistaxis per month (CI 95%, 5.5-27.6). The median number of epistaxis episodes per month was 22.1 episodes in the placebo arm vs. 23.3 episodes in the TA arm. No thrombophlebitis was observed.
Conclusions: In the ATERO study, we demonstrated a significant decrease in the duration of epistaxis in HHT patients taking TA. No safety issues were recorded in our cohort of patients.
Keywords: Osler-Rendu disease; epistaxis; hereditary hemorrhagic telangiectasia; randomized controlled trial; tranexamic acid.
© 2014 International Society on Thrombosis and Haemostasis.
Source: PubMed